AltruBio
PrivateLast Round
Series B
May 21, 2024
Total Funding Raised
$288M
Company Overview
AltruBio is a privately held, clinical-stage biotechnology company that develops novel antibody therapeutics for immunological and inflammatory diseases. The company's lead candidates, ALTB-268 and ALTB-168 (neihulizumab), are first-in-class immune checkpoint enhancers that target the PSGL-1 protein to down-regulate chronically activated T-cells. Originally founded as AbGenomics with a focus on oncology, the company rebranded to AltruBio in 2020, shifting its strategy to immunology. The company's lead program is in Phase 2 trials for ulcerative colitis (UC). AltruBio secured up to $225 million in an oversubscribed Series B financing in May 2024 to advance its clinical programs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AltruBio Comps
Public and private peers based on sector, stage, and business model.
AltruBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 21, 2024 | ||||
| Series A | Apr 15, 2021 | ||||
| VC Round | Aug 15, 2014 | ||||
| VC Round | Jun 22, 2012 |
Key People
Founding team and executive leadership
AltruBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| RA Capital Management | Series B |
| CAM Capital | Series A |
| aMoon | Series B, Series A |
| BVF Partners L.P. | Series A |
| Blackstone Multi-Asset Investing | Series B |
| Blackstone Funds | Series B |
AltruBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AltruBio's valuation, stock price, and market status.
